We are pleased to advise Optiscan was featured in The Australian yesterday.

Included in the Business Review section, the article “Can the magic acronyms ‘AI’ and ‘FDA’ see Optiscan probe new heights?” was written by Tim Boreham, and covers key highlights from FY23 including clinical progress, successful capital raising and milestones in AI and Telepathology, and provides a glimpse into the future of precision surgery and digital pathology following the unveiling of our new surgical device.